Evaluating the role of IL-9 on cancer development in a mouse model of BC (HER2+ and TN models) also demonstrated that IL-9 deficiency through neutralizing antibodies or deleting endogenous IL-9 led to priming host tumor-specific T-cells, acquiring immunologic memory, and the early rejection of BC [114]. This evidence concerns the gene IL9 and breast cancer.